Supplemental materials to:

Dapagliflozin and kidney outcomes in hospitalized patients with COVID-19 infection: An analysis of the DARE-19 randomized controlled trial

Heerspink HH et al.

Contents


| Supplemental Figure 1: The secondary kidney outcome by pre-specified subgroups | 2 |
|----------------------------------------------------------------------------------------------|---|
| Supplemental Figure 2: LS Mean eGFR (standard error) for all recorded local standard of care | |
| assessments in participants with eGFR <60 and \geq 60 mL/min/1.73m ² | 3 |
| | |


Supplemental Figure 3: Histogram of the change in eGFR from baseline to Day 3 in participants with baseline eGFR <60 mL/min/1.73m² (A), and those with baseline eGFR \geq 60 mL/min/1.73m² (B)......4

Supplemental Figure 1: The secondary kidney outcome by pre-specified subgroups

| Subgroup | Dapagliflozin | Placebo | Hazard Ratio (95% CI) | P-interaction | |
|---------------------------|---------------|---------|----------------------------------------|---------------|--|
| no. of patients/total no. | | | | | |
| All patients | 48/625 | 65/625 | 0.74 (0.50, 1.07) | | |
| Age | | | | 0.27 | |
| <60 yr | 8/286 | 15/265 | ► 0.49 (0.21, 1.16) | | |
| ≥60 yr | 40/339 | 50/360 | 0.84 (0.55, 1.28) | | |
| BMI at enrollment | | | | 0.34 | |
| <30 kg/m ² | 31/327 | 45/315 | 0.63 (0.40, 1.00) | | |
| ≥30 kg/m ² | 17/296 | 20/305 | 0.93 (0.49, 1.80) | | |
| Sex | | | | 0.14 | |
| Male | 27/365 | 44/352 | L 0.58 (0.36, 0.95) | | |
| Female | 21/260 | 21/273 | ⊢−−−↓ 1.05 (0.57, 1.92) | | |
| Race | | | | 0.21 | |
| White | 33/452 | 50/459 | 0.65 (0.42, 1.02) | | |
| Black | 10/85 | 6/84 | ► ► ► ► ► ► ► ► ► ► ► ► ► ► ► ► ► ► ► | | |
| Asian | 1/35 | 5/29 | <───────────────────────────────────── | | |
| Other | 4/51 | 3/46 | ► ► ► ► ► ► ► ► ► ► ► ► ► ► ► ► ► ► ► | | |
| Country | | | i | 0.91 | |
| Argentina | 1/13 | 4/14 | ← ■ 0.21 (0.02, 1.87) | | |
| Brazil | 35/382 | 42/380 | □ □ □ □ 0.82 (0.52, 1.29) | | |
| Canada | 0/2 | 2/2 | NC | | |
| India | 0/26 | 2/24 | NC | | |
| Mexico | 2/59 | 3/59 | < ■ 0.56 (0.09, 3.61) | | |
| UK | 0/0 | 0/2 | NC NC | | |
| USA | 10/143 | 12/144 | L 0.98 (0.42, 2.27) | | |
| History of hypertension | | | ! | 0.21 | |
| Yes | 38/526 | 58/534 | □ 0.66 (0.44, 1.01) | | |
| No | 10/99 | 7/91 | ⊢ 1 .46 (0.55, 3.88) | | |
| History of ACVD | | | i | 0.89 | |
| Yes | 12/93 | 19/106 | ► ► ► ► ► ► ► ► ► ► ► ► ► ► ► ► ► ► ► | | |
| No | 36/532 | 46/518 | □ □ □ □ 0.75 (0.48, 1.16) | | |
| History of heart failure | | | | 0.58 | |
| Yes | 6/44 | 6/46 | ► ► ► ► ► ► ► ► ► ► ► ► ► ► ► ► ► ► ► | | |
| No | 42/581 | 59/579 | ⊢ – – – – – – – – – – | | |
| History of diabetes | | | ! | 0.74 | |
| Yes | 27/312 | 37/324 | ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● | | |
| No | 21/312 | 27/300 | ► ► ► ► ► 0.70 (0.39, 1.26) | | |
| History of COPD | | | i | 0.71 | |
| Yes | 5/25 | 5/32 | ► 1.27 (0.31, 5.22) | | |
| No | 43/600 | 60/593 | → → → → 0.72 (0.48, 1.06) | | |
| NT-proBNP | | | | 0.18 | |
| ≤Median | 15/253 | 14/254 | L 1.09 (0.52, 2.28) | | |
| >Median | 21/247 | 35/257 | ► 0.58 (0.33, 0.99) | | |
| hs Troponin | | | ! | 0.98 | |
| ≤Median | 16/279 | 20/274 | → 0.79 (0.41, 1.54) | | |
| >Median | 27/266 | 35/281 | 0.82 (0.49, 1.35) | | |
| hs CRP | | | i | 1.00 | |
| ≤Median | 21/292 | 28/287 | ► ► ► ► ► ► ► ► ► ► ► ► ► ► ► ► ► ► ► | | |
| >Median | 22/289 | 31/289 | □ □ □ □ 0.75 (0.43, 1.29) | | |
| D-dimer | | | | 0.34 | |
| ≤Median | 16/288 | 26/280 | □ □ □ □ 0 .62 (0.33, 1.16) | | |
| >Median | 29/283 | 32/277 | → → → → → → → → → → | | |
| | | | | | |
| | | | 0.2 0.5 1.0 2.0 3.0 4.0 | | |
| | | • | Dapagliflozin Better Placebo Better | | |
| | | | | | |

2





Supplemental Figure 3: Histogram of the change in eGFR from baseline to Day 3 in participants with baseline eGFR <60 mL/min/1.73m² (A), and those with baseline eGFR \geq 60 mL/min/1.73m² (B)

